Filing Flows › Viridian Therapeutics (VRDN) › Q2 2025
Viridian Therapeutics (VRDN) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Viridian Therapeutics (VRDN) reported revenue of $75K for the second quarter 2025 (Q2 2025), +4% from a year earlier and +4% from the quarter before.
Viridian Therapeutics, Q2 2025: revenue $75K (+4% year over year), net loss $101M, operating cash flow −$75.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $75K | +4% | +4% |
| Operating profit | −$107M | — | — |
| Net earnings | −$101M | — | — |
| Operating cash flow | −$75.4M | — | — |
What changed
Revenue was $75K in Q2 2025, up 4% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $106.8M, an operating margin of -142356.0%. Total costs grew 48% against revenue growth of 4%. The fastest-growing cost line was Research & development (+54%). The quarter ended with a net loss of $100.7M, wider than the previous quarter's $86.9M loss.
Operating cash flow was −$75.4M. Non-cash charges added back $113K of depreciation and amortization and $10.8M of share-based compensation. Working capital and other items added $14.4M. Capital expenditures of $42K exceeded it, leaving free cash flow of −$75.4M.
Questions
What was Viridian Therapeutics' revenue in the second quarter 2025?
Viridian Therapeutics (VRDN) reported revenue of $75K for the second quarter 2025 (Q2 2025), +4% from a year earlier and +4% from the quarter before.